Michael R. Zalutsky

Prof. Michael R. Zalutsky

Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2007 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Michael R. ZalutskyMichael R. Zalutsky
Michael R. Zalutsky
DRDavid A. Reardon
David A. Reardon
GAGamal Akabani
Gamal Akabani
RCR. Edward Coleman
R. Edward Coleman
AFAllan H. Friedman
Allan H. Friedman
DBDarell D. Bigner
Darell D. Bigner
α-Particle–emitting radionuclides, such as 211At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-particles than of β-particles, 211At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors. The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors. Methods: Chimeric antitenascin monoclonal antibody 81C6 (ch81C6) (10 mg) was labeled with 71–347 MBq of 211At by use of N-succinimidyl 3-[211At]astatobenzoate. Eighteen patients were treated with 211At-labeled ch81C6 (211At-ch81C6) administered into a surgically created resection cavity (SCRC) and then with salvage chemotherapy. Serial γ-camera imaging and blood sampling over 24 h were performed. Results: A total of 96.7% ± 3.6% (mean ± SD) of 211At decays occurred in the SCRC, and the mean blood-pool percentage injected dose was ≤0.3. No patient experienced dose-limiting toxicity, and the maximum tolerated dose was not identified. Six patients experienced grade 2 neurotoxicity within 6 wk of 211At-ch81C6 administration; this neurotoxicity resolved fully in all but 1 patient. No toxicities of grade 3 or higher were attributable to the treatment. No patient required repeat surgery for radionecrosis. The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively. Conclusion: This study provides proof of concept for regional targeted radiotherapy with 211At-labeled molecules in oncology. Specifically, the regional administration of 211At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

1 July 2011 in Current Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
Michael R. ZalutskyMichael R. Zalutsky
Michael R. Zalutsky
MPMarek Pruszyński
Marek Pruszyński
The 7.2-h half life radiohalogen 211At offers many potential advantages for targeted α-particle therapy; however, its use for this purpose is constrained by its limited availability. Astatine-211 can be produced in reasonable yield from natural bismuth targets via the 209Bi(α,2n)211At nuclear reaction utilizing straightforward methods. There is some debate as to the best incident α-particle energy for maximizing 211At production while minimizing production of 210At, which is problematic because of its 138.4-day half life α-particle emitting daughter, 210Po. The intrinsic cost for producing 211At is reasonably modest and comparable to that of commercially available 123I. The major impediment to 211At availability is attributed to the need for a medium energy α-particle beam for its production. On the other hand, there are about 30 cyclotrons in the world that have the beam characteristics required for 211At production.

1 September 2000 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Michael R. ZalutskyMichael R. Zalutsky
Michael R. Zalutsky
GVGanesan Vaidyanathan
Ganesan Vaidyanathan
Targeted radiotherapy or endoradiotherapy is an appealing approach to cancer treatment because of the potential for delivering curative doses of radiation to tumor while sparing normal tissues. Radionuclides that decay by the emission of a-particles such as the heavy halogen astatine-211 ( 211 At) offer the exciting prospect of combining cell-specific molecular targets with radiation having a range in tissue of only a few cell diameters. Herein, the radiobiological advantages of alpha-particle targeted radiotherapy will be reviewed, and the rationale for using 211 At for this purpose will be described. The chemistry of astatine is similar to that of iodine; however, there are important differences which make the synthesis and evaluation of 211 At-labeled compounds more challenging. Perhaps the most successful approach that has been developed involves the astatodemetallation of tin, silicon or mercury precursors. Astatine-211 labeled agents that have been investigated for targeted radiotherapy include ( 211 At)astatide, 211 At- labeled particulates, 211 At-labeled naphthoquinone derivatives, 211 At-labeled methylene blue, 211 At-labeled DNA precursors, meta-[211 At]astatobenzylguanidine, 211 At-labeled biotin conjugates, 211 At-labeled bisphosphonates, and 211 At-labeled antibodies and antibody fragments. The status of these 211 At-labeled compounds will be discussed in terms of their labeling chemistry, cytotoxicity in cell culture, as well as their tissue distribution and therapeutic efficacy in animal models of human cancers. Finally, an update on the status of the first clinical trial with an 211 At-labeled targeted therapeutic, 211 At-labeled chimeric anti-tenascin antibody 81C6, will be provided.


1 October 2007 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Michael R. ZalutskyMichael R. Zalutsky
Michael R. Zalutsky
DRDavid A. Reardon
David A. Reardon
OPOscar R. Pozzi
Oscar R. Pozzi
GVGanesan Vaidyanathan
Ganesan Vaidyanathan
DBDarell D. Bigner
Darell D. Bigner

10 June 2021 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
YFYutian Feng
Yutian Feng
Michael R. ZalutskyMichael R. Zalutsky
Michael R. Zalutsky